A Phase II Study of Busulfan & Melphalan as Conditioning Regimen for ASCT in Patients Who Received Bortezomib Based Induction for Newly Diagnosed Multiple Myeloma Followed by Lenalidomide Maintenance Until Progression

Trial Profile

A Phase II Study of Busulfan & Melphalan as Conditioning Regimen for ASCT in Patients Who Received Bortezomib Based Induction for Newly Diagnosed Multiple Myeloma Followed by Lenalidomide Maintenance Until Progression

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Dec 2016

At a glance

  • Drugs Busulfan (Primary) ; Lenalidomide (Primary) ; Melphalan (Primary) ; Autologous stem cell therapy
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms BuMelMCRN001
  • Most Recent Events

    • 06 Dec 2016 Results analysing Minimal Residual Disease (MRD) and Involved Serum Hevylite Chain (HLC) ratio assessments, presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 01 Dec 2016 Planned End Date changed from 1 Jul 2021 to 1 Jul 2022.
    • 01 Dec 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Apr 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top